| Open Trial |
Description |
| 0116 |
A 2 part Phase I/II study of extended field external irradiation and intracavitary brachytherapy combined with chemotherapy (weekly Cisplatin - arm 1) and Amifostine (weekly Cisplatin and Amifostine - arm 2) in carcinoma of the cervix with positive para-a
Contact: Dr. J. Radwan |
| PIE |
Phase II trial of Cisplatin, Irinotecan, Epirubicin administered every 3 weeks in patients with unresectable, locally advanced, metastatic cervical cancer.
Contact: Dr. Mark Carey |
| EN.5 |
A phase 3 randomized trial comparing total abdominal hysterectomy and bilateral salpingo-oophorectomy versus total abdominal hysterectomy and bilateral salpingo-oophorectomy plus adjuvant pelvic radiation in state (intermediate risk) carcinoma of the endo
Contact: Dr. Mark Carey |
| NCIC CTG OV.16 |
A phase III study of Cisplatin plus Topotecan followed by Paclitaxel plus Carboplatin versus Paclitaxel plus Carboplatin as first line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer.
Contact: Dr. Mark Carey |
| BEVA-OV |
A Phase II trial of Bevacizumab and low dose oral Cyclophosphamide in recurrent ovarian cancer, primary peritoneal carcinoma.
Contact: Dr. Mark Carey |
|
Link to London Regional Cancer Program |
